Biogen Idec Inc (BIIB): Biogen Idec Management Discusses Q3 2013 Results ... Seeking Alpha Also in mid-2014, we look forward to seeing Phase III data for daclizumab in relapsing-remitting MS. Data from the daclizumab Phase IIb registrational study point at strong efficacy in annualized relapse rate and MRI measures of disease activity and ... |
